Christina Rizopoulos Valauri Acquires 19,000 Shares of Tivic Health Systems (NASDAQ:TIVC) Stock

Tivic Health Systems, Inc. (NASDAQ:TIVC) Director Christina Rizopoulos Valauri bought 19,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were purchased at an average cost of $0.95 per share, with a total value of $18,050.00. Following the acquisition, the director directly owned 19,000 shares of the company’s stock, valued at approximately $18,050. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tivic Health Systems Trading Down 2.4%

NASDAQ TIVC traded down $0.02 during trading on Thursday, reaching $0.99. The company’s stock had a trading volume of 21,990 shares, compared to its average volume of 224,944. The firm has a 50 day moving average price of $0.94 and a 200 day moving average price of $1.77. Tivic Health Systems, Inc. has a 12 month low of $0.72 and a 12 month high of $13.23. The firm has a market capitalization of $1.75 million, a price-to-earnings ratio of -0.15 and a beta of 1.83.

Tivic Health Systems (NASDAQ:TIVC) last announced its earnings results on Wednesday, April 1st. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($408.00) by $406.97. Tivic Health Systems had a negative net margin of 1,557.26% and a negative return on equity of 202.20%.

Institutional Investors Weigh In On Tivic Health Systems

An institutional investor recently bought a new position in Tivic Health Systems stock. Marex Group plc acquired a new stake in Tivic Health Systems, Inc. (NASDAQ:TIVC) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 39,283 shares of the company’s stock, valued at approximately $163,000. Marex Group plc owned approximately 3.64% of Tivic Health Systems as of its most recent SEC filing. 4.25% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tivic Health Systems in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Tivic Health Systems currently has a consensus rating of “Sell”.

Tivic Health Systems Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.